Lv11
44 积分 2024-09-09 加入
Efficacy and safety of one-time autologous tumor-infiltrating lymphocyte cell therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
1小时前
已完结
Alopecia associated with the use of semaglutide and tirzepatide: A disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2022 to 2023
10天前
已完结
Drugs Withdrawn from the Canadian Market for Safety and Effectiveness Reasons, 1990–2024: A Cross-Sectional Study
13天前
已完结
Oral iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria: final 48-week results from the open-label, randomised, phase 3 APPLY-PNH trial in anti-C5-treated patients and the open-label, single-arm, phase 3 APPOINT-PNH trial in patients previously untreated with complement inhibitors
15天前
已完结
Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy
18天前
已完结
CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial
2个月前
已完结
Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials
2个月前
已完结
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity
2个月前
已完结
First‐in‐human study of HDM1002, a GLP‐1 receptor agonist: Safety, tolerability, pharmacokinetics and pharmacodynamics of escalating single oral doses in healthy volunteers
2个月前
已完结
Consensus statement on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: Localized scleroderma, systemic sclerosis and overlap syndromes
4个月前
已完结
皖公网安备34019202002308
